The DOI matches its Crossref record.
Let’s talk about lipid nanoparticles
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, bioPROTACs would most likely be delivered as mRNA or DNA constructs via a viral vector gene delivery system204–206 or in a nanoparticle207–209.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [209]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorted by citations
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
Nanomaterials: An overview of synthesis, classification, characterization, and applications
Mekuye, B., & Abera, B. (2023) · Nano Select · doi:10.1002/nano.202300038 · Cited by 746
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719
Mehta, M., Bui, T. A., Yang, X., Aksoy, Y. A., Goldys, E. M., & Deng, W. (2023) · ACS Materials Au · doi:10.1021/acsmaterialsau.3c00032 · Cited by 776
“10,217 Ensuring regulatory compliance for LNPs is paramount to guarantee their safety and effectiveness in therapeutic applications.”
BackgroundNon-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects
Zu, H., & Gao, D. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00608-7 · Cited by 505
Nanoparticles in the clinic: An update post COVID ‐19 vaccines
Anselmo, A. C., & Mitragotri, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10246 · Cited by 364
Tariq, H., Batool, S., Asif, S., Ali, M., & Abbasi, B. H. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.790121 · Cited by 249
Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies
Cid, R., & Bolívar, J. (2021) · Biomolecules · doi:10.3390/biom11081072 · Cited by 176
Recent Advances in Lipid Nanoparticles for Delivery of mRNA
Yang, L., Gong, L., Wang, P., Zhao, X., Zhao, F. H., Zhang, Z., Li, Y., & Huang, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122682 · Cited by 190
Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids
Prakash, G., Shokr, A., Willemen, N. G. A., Bashir, S. M., Shin, S. R., & Hassan, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114197 · Cited by 122
Zhang, C., Ma, Y., Zhang, J., Kuo, J. C., Zhang, Z., Xie, H., Zhu, J., & Liu, T. (2022) · Molecules · doi:10.3390/molecules27061943 · Cited by 95
Bondarenko, O. M., & Saarma, M. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.682597 · Cited by 90
Dogbey, D. M., Torres, V. E. S., Fajemisin, E. A., Mpondo, L., Ngwenya, T., Akinrinmade, O. A., Perriman, A. W., & Barth, S. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01362-3 · Cited by 97
Size and Charge Characterization of Lipid Nanoparticles for mRNA Vaccines
Malburet, C., Leclercq, L., Cotte, J., Thiebaud, J., Bazin, E., Garinot, M., & Cottet, H. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04778 · Cited by 75
Advanced delivery systems for peptide antibiotics
Cesaro, A., Lin, S., Pardi, N., & de la Fuente‐Núñez, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114733 · Cited by 67
Lipid nanoparticles for enhancing oral bioavailability
Gangavarapu, A., Tapia-Lopez, L. V., Sarkar, B., Pena‐Zacarias, J., Badruddoza, A. Z. M., & Nurunnabi, M. (2024) · Nanoscale · doi:10.1039/d4nr01487a · Cited by 64
Lysosomal nanotoxicity: Impact of nanomedicines on lysosomal function
Uzhytchak, M., Smolková, B., Lunová, M., Frtús, A., Jirsa, M., Dejneka, A., & Lunov, O. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114828 · Cited by 61
Mahmud, N., Anik, M. I., Hossain, M. K., Khan, M. I., Uddin, S., Ashrafuzzaman, M., & Rahaman, M. M. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00123 · Cited by 53
The Potential of Cell-Penetrating Peptides for mRNA Delivery to Cancer Cells
Kim, Y., Kim, H., Kim, E. H., Jang, H., Jang, Y., Chi, S.-G., Yang, Y., & Kim, S. H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061271 · Cited by 50
High‐Precision Synthesis of RNA‐Loaded Lipid Nanoparticles for Biomedical Applications
Seo, H., Jeon, L., Kwon, J., & Lee, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203033 · Cited by 54
Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines
Rapaka, R. R., Cross, A. S., & McArthur, M. A. (2021) · Vaccines · doi:10.3390/vaccines9080820 · Cited by 48
Cordeiro, A. S., Patil‐Sen, Y., Shivkumar, M., Patel, R., Khedr, A., & Elsawy, M. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122091 · Cited by 51
From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines
Lopez-Cantu, D. O., Wang, X., Carrasco-Magallanes, H., Afewerki, S., Zhang, X., Bonventre, J. V., & Ruiz‐Esparza, G. U. (2022) · Nano-Micro Letters · doi:10.1007/s40820-021-00771-8 · Cited by 49
Recent advances in carbon quantum dots for gene delivery: A comprehensive review
Othman, H. O., Anwer, E. T., Ali, D. S., Hassan, R. O., Mahmood, E. E., Ahmed, R. A., Muhammad, R. F., & Smaoui, S. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31236 · Cited by 49
Metanat, Y., Viktor, P., Amajd, A., Kaur, I., Hamed, A. M., Al-Abadi, N. K. A., Alwan, N. H., Chaitanya, M., Natrayan, L., Ghildiyal, P., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122683 · Cited by 49
Ou, L., Chen, H., Yuan, B., & Yang, K. (2022) · ACS Nano · doi:10.1021/acsnano.2c04774 · Cited by 42
Nanoparticle approaches against SARS-CoV-2 infection
Duan, Y., Wang, S., Zhang, Q., Gao, W., & Zhang, L. (2021) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2021.100964 · Cited by 40
Lee, J. H., Han, J. P., Song, D. W., Lee, G. S., Choi, B. S., Kim, M., Lee, Y., Kim, S., Lee, H., & Yeom, S. C. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.03.008 · Cited by 40
Yang, K.-C., Lin, J.-C., Tsai, H.-H., Hsu, C.-Y., Shih, V., & Hu, C.-M. J. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00965-y · Cited by 39
Metkar, S. P., Fernandes, G. J., Navti, P. D., Nikam, A. N., Kudarha, R. R., Dhas, N. L., Seetharam, R. N., Venkata, S. K., Rao, B. S. S., & Mutalik, S. (2023) · OpenNano · doi:10.1016/j.onano.2023.100159 · Cited by 39
Non-viral nucleic acid delivery approach: A boon for state-of-the-art gene delivery
Sahu, K. K., Pradhan, M., Singh, D., Singh, M. R., & Yadav, D. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104152 · Cited by 36
The Internal Nanostructure of Lipid Nanoparticles Influences Their Diverse Cellular Uptake Pathways
Yap, S. L., Dyett, B., Hobro, A. J., Nguyen, H. T. N., Smith, N. I., Drummond, C. J., Conn, C. E., & Tran, N. L. (2025) · Small · doi:10.1002/smll.202500903 · Cited by 38
Spray-Dried Nanolipid Powders for Pulmonary Drug Delivery: A Comprehensive Mini Review
Elella, M. H. A., Khatib, A. O. A., & Al-Obaidi, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050680 · Cited by 29
“Due to their small, spherical size, these nanoparticles can deliver drugs into cells via endocytosis and release the cargo into the cytoplasm [25].”
BackgroundTaylor Dispersion Analysis to support lipid-nanoparticle formulations for mRNA vaccines
Malburet, C., Leclercq, L., Cotte, J., Thiebaud, J., Bazin, E., Garinot, M., & Cottet, H. (2022) · Gene Therapy · doi:10.1038/s41434-022-00370-1 · Cited by 29
Bouazzaoui, A., & Abdellatif, A. A. H. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100500 · Cited by 31
“To improve the LNPs stability, biodistribution and tolerability, other components could be added such as cholesterol, phospholipids and PEGylated [111,113,114].”
BackgroundMicrofluidic Technology for the Production of Hybrid Nanomedicines
Ottonelli, I., Duskey, J. T., Rinaldi, A., Grazioli, M. V., Parmeggiani, I., Vandelli, M. A., Wang, L. Z., Prud’homme, R. K., Tosi, G., & Ruozi, B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091495 · Cited by 27
Ferreri, C., Ferocino, A., Batani, G., Chatgilialoglu, C., Randi, V., Riontino, M. V., Vetica, F., & Sansone, A. (2023) · Biomolecules · doi:10.3390/biom13050730 · Cited by 26
Cancer Nanopharmaceuticals: Physicochemical Characterization and In Vitro/In Vivo Applications
Zielińska, A., Szalata, M., Gorczyński, A., Karczewski, J., Eder, P., Severino, P. B., Cabeda, J. M., Souto, E. B., & Słomski, R. (2021) · Cancers · doi:10.3390/cancers13081896 · Cited by 30
Copper-Silver Nanohybrids: SARS-CoV-2 Inhibitory Surfaces
Mosselhy, D. A., Kareinen, L., Kivistö, I., et al. (2021) · Nanomaterials · doi:10.3390/nano11071820 · Cited by 25
Burgos‐Panadero, R., Moukhtari, S. H. E., Noguera, I., Rodríguez‐Nogales, C., Martín-Vañó, S., Vicente‐Munuera, P., Cañete, A., Navarro, S., Blanco‐Prieto, M. J., & Noguera, R. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121058 · Cited by 24
Farabegoli, F., & Pinheiro, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.809706 · Cited by 25
“Among the different types of NPs, lipid-based NPs emerge as the most Frontiers in Pharmacology | www.frontiersin.org April 2022 | Volume 13 | Article 8097062 promising drug delivery systems because their composition is based on lipids, which also exist in the human body, making the NPs biocompatible and biodegradable…”
BackgroundMethodInfluentialChary, M. A., Barbuto, A. F., Izadmehr, S., Tarsillo, M., Fleischer, E., & Burns, M. M. (2023) · Journal of Medical Toxicology · doi:10.1007/s13181-023-00931-9 · Cited by 25
Puri, A. V., Mohite, P. B., Munde, S. V., Ade, N., Ramole, A., Pillai, D., Nagare, S., Mahadik, S., & Singh, S. K. (2025) · Journal of Dispersion Science and Technology · doi:10.1080/01932691.2025.2496388 · Cited by 22
Harnessing DNA for Immunotherapy: Cancer, Infectious Diseases, and Beyond
Wang, Y., Chen‐Mayfield, T., Li, Z., Younis, M. H., Cai, W., & Hu, Q. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202112273 · Cited by 23
Lamptey, R. N. L., Sun, C., Layek, B., & Singh, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032213 · Cited by 24
Ahmed, T., Liu, F.-C. F., & Wu, X. Y. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2318459 · Cited by 23
Nanoscience versus Viruses: The SARS‐CoV‐2 Case
Gościańska, J., Freund, R., & Wuttke, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202107826 · Cited by 21
Targeting the Kidneys at the Nanoscale: Nanotechnology in Nephrology
Vasylaki, A., Ghosh, P., Jaimes, E. A., & Williams, R. M. (2024) · Kidney360 · doi:10.34067/kid.0000000000000400 · Cited by 21
Idris, A. H., Abdullah, C. A. C., Yusof, N. A., Asmawi, A. A., & Rahman, M. B. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051319 · Cited by 21
Roffo, F., Ponsiglione, A. M., Netti, P. A., & Torino, E. (2022) · Biomedicines · doi:10.3390/biomedicines10020438 · Cited by 18
Zhu, D., Chen, W., Lin, W., Li, Y., & Liu, X. (2021) · Biomedical Materials · doi:10.1088/1748-605x/ac0a8f · Cited by 17
Molaei, Z., Jabbarpour, Z., Omidkhoda, A., & Ahmadbeigi, N. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03848-4 · Cited by 17
Multimodal imaging distribution assessment of a liposomal antibiotic in an infectious disease model
Cheng, S., Groseclose, M. R., Mininger, C., Bergström, M., Zhang, L., Lenhard, S. C., Skedzielewski, T., Kelley, Z. D., Comroe, D., Hong, H., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.061 · Cited by 15
Nanoparticles in Subunit Vaccines: Immunological Foundations, Categories, and Applications
Liang, J., Yao, L., Liu, Z., Chen, Y., Lin, Y., & Tian, T. (2024) · Small · doi:10.1002/smll.202407649 · Cited by 17
Damasceno, D. H. P., Amaral, A. A., Silva, C. A., & Silva, A. C. S. E. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210902094254 · Cited by 15
Non‐coding RNAs to treat vascular smooth muscle cell dysfunction
Brown, S., Klimi, E., Bakker, W. A. M., Beqqali, A., & Baker, A. H. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16409 · Cited by 15
“…efficiency and reduced side effects following systemic administration, which resulted in their extensive use as delivery systems for diverse therapeutic applications ( ‘ Let's talk about lipid nanoparticles ’ , 2021; Tenchov et al., 2021), including to the vasculature (Flores et al., 2019).”
Li, M., Schroder, R. V., Ozuguzel, U., Corts, T. M., Liu, Y., Zhao, Y., Xu, W., Ling, J., Templeton, A. C., Chaudhuri, B., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01437 · Cited by 16
Vosoughi, P., Naghib, S. M., Jafari, T., & Kangarshahi, B. M. (2025) · Carbohydrate Polymer Technologies and Applications · doi:10.1016/j.carpta.2025.100805 · Cited by 18
Dynamics of intracellular clusters of nanoparticles
Alexandrov, D. V., Nickolay Korabel, A., Currell, F. J., & Fedotov, S. P. (2022) · Cancer Nanotechnology · doi:10.1186/s12645-022-00118-x · Cited by 15
“(10) using the tabulated formula [see expression 22.95 in Ditkin and Prudnikov (1965)].”
MethodInfluentialHaro-Martínez, E., Muscolino, E., Moral, N., Durán, J., & Fornaguera, C. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01887-9 · Cited by 18
“Lipid NPs (LNPs) are typically composed of ionizable lipids, allowing for the nanocarrier to assume a positive charge at low pH to facilitate RNA complexation, and a neutral charge at physiological pH to reduce toxicity arising from cationic charges [207].”
The surface force balance: direct measurement of interactions in fluids and soft matter
Hayler, H. J., Groves, T., Guerrini, A., Southam, A., Zheng, W., & Perkin, S. (2024) · Reports on Progress in Physics · doi:10.1088/1361-6633/ad2b9b · Cited by 20
“…from medicine to geology reaches the nano-scale: drug delivery now involves ‘nanoparticles’ targeted to interact with interfaces in specific ways [34]; energy storage involves battery materials engineered at the nanoscale to optimise energy density and cycling dynamics; [35] and micro-electronic…”
Nanocarrier-based gene delivery for immune cell engineering
Gharatape, A., Abandansari, H. S., Seifalian, A. M., Majidi, R. F., & Basiri, M. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02279j · Cited by 16
The rationale for the treatment of long-Covid symptoms – A cardiologist's view
Schieffer, E., & Schieffer, B. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.992686 · Cited by 13
The Potential of Epigallocatechin Gallate in Targeting Cancer Stem Cells: A Comprehensive Review
Chaudhuri, R., Samanta, A., Saha, P., Ghosh, S., & Sinha, D. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673281666231227053726 · Cited by 13
Strategies for Browning Agent Delivery
Zhang, W., Sheng, T., Gu, Z., & Zhang, Y. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03081-1 · Cited by 14
Viruses as Living Systems—A Metacybernetic View
Yolles, M. I., & Frieden, R. (2022) · Systems · doi:10.3390/systems10030070 · Cited by 18
Application of nanoparticles to target tumor blood vessels as a promising cancer treatment strategy
Lorenc, P., Dams‐Kozlowska, H., Guzniczak, N., & Florczak, A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118038 · Cited by 14
Lipid-Based Intelligent Vehicle Capabilitized with Physical and Physiological Activation
Zhang, F., Xia, B., Sun, J., Wang, Y., Wang, J., Xu, F., Chen, J., Lu, M., Yao, X., Timashev, P. S., et al. (2022) · Research · doi:10.34133/2022/9808429 · Cited by 12
Micro‐ and Nanomanufacturing for Biomedical Applications and Nanomedicine: A Perspective
Wang, F., Harker, A. H., Edirisinghe, M. J., & Parhizkar, M. (2023) · Small Science · doi:10.1002/smsc.202300039 · Cited by 12
Vu, M. N., Pilapitiya, D., Kelly, A., Koutsakos, M., Kent, S. J., Juno, J. A., Tan, H., & Wheatley, A. K. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102547 · Cited by 15
O’Hare, M., Miller, W. P., Arévalo-Alquichire, S., Amarnani, D., Apriani, E., Perez-Corredor, P. A., Mariño, C., Shu, D. Y., Vanderleest, T. E., Muriel‐Torres, A. F., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adh0994 · Cited by 12
Interfacing Biomaterials with Synthetic T Cell Immunity
Su, F., Mac, Q. D., Sivakumar, A., & Kwong, G. A. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100157 · Cited by 10
Analytical approach for identification and mechanistic insights into mRNA-lipid adduct formation
Peronin, S., Malburet, C., Hassan, C., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102684 · Cited by 10
“4,5 Numerous RNA delivery systems have been developed over the years, 6–8 among which the lipid nanoparticle (LNPs) platform stands out as a gold standard.”
Lipid nanoparticles for pulmonary fibrosis: A comprehensive review
Dhara, T. K., Khawas, S., & Sharma, N. (2024) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2024.102319 · Cited by 10
Singh, M., & Venkatas, J. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220609115109 · Cited by 9
Success of nano-vaccines against COVID-19: a transformation in nanomedicine
Sarangi, M. K., Padhi, S. K., Rath, G., Nanda, S. S., & Yi, D. K. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2148659 · Cited by 11
An overview on recent patents and technologies on nanoparticles for nucleic acid delivery
Fonseca, L. M. D. S., Machado, B. A. S., Oliveira, F. O., Santos, J. R. D. J., da Silva, J. W., Hodel, K. V. S., Rosatti, B. G., Pinto, C. D., & Soares, M. B. P. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2338097 · Cited by 11
“LNPs are sub-micron-sized particles that consist of various types of lipids, including ionizable cationic lipids, along with encapsulated nucleic acid cargo [18,78].”
BackgroundKwak, G., Lee, D., & Suk, J. S. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2282535 · Cited by 9
“Further, negatively charged nucleic acids are electrostatically repelled by the negatively charged cell membrane, which is of particular concern for large nucleic acids, such as DNA and messenger RNA (mRNA) [3,4].”
BackgroundmRNA Vaccination: An Outlook on Innate Sensing and Adaptive Immune Responses
Doost, J. S., Fazel, F., Boodhoo, N., & Sharif, S. (2024) · Viruses · doi:10.3390/v16091404 · Cited by 9
“Due to their size and surface charge characteristics, cells internalize LNPs through endocytosis, and lipid ionizations under low-pH Viruses 2024 , 16 , 1404 3 of 14 conditions facilitate their escape from endosomes, thereby enabling release of the cargo into the cytoplasm [32].”
BackgroundEngineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats
Dong, C., & Wang, B. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100122 · Cited by 9
Lipid membrane-based therapeutics and diagnostics
de Carvalho, P. M. B., Makowski, M., Domingues, M. M., Martins, I. C., & Santos, N. C. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108858 · Cited by 7
Cui, Z., Liang, W., Li, J., & Bai, Z. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148389 · Cited by 6
Anders, A. G., & Ruotolo, B. T. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c11066 · Cited by 7
Evaluation of a self-amplifying mRNA reporter vaccine in explant models of broiler chickens
Snoeck, J., Chiers, K., Tam, Y. K., Sanders, N. N., & Garmyn, A. (2023) · Poultry Science · doi:10.1016/j.psj.2023.103078 · Cited by 7
“Ideally, they are less than 100 nm and have a close to neutral surface charge in order to allow traf fi cking to lymphoid tissue and be taken up by the necessary cells (No Authors Listed, 2021).”
BackgroundLiver fibrosis pathologies and potentials of RNA based therapeutics modalities
Diwan, R., Gaytan, S. L., Bhatt, H. N., Pena‐Zacarias, J., & Nurunnabi, M. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01551-8 · Cited by 6
Nanomedicine for Diagnosis and Treatment of Cardiac Fibrosis
Montano-Peguero, Y., Verdejo, H., Riquelme, J. A., Kogan, M. J., & Lavandero, S. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s520967 · Cited by 7
“126,127 There is an excellent platform of LNPs, starting from: liposomes, liposomes encapsulating hydrophobic and hydrophilic drugs, antibody functionalized liposomes, sterically stabilized, and PEG functionalized liposomes.”
Nanotechnology in microbial food safety
Pal, A., & Bhunia, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822858-6.00020-0 · Cited by 5
Lipid nanoparticle mediated mRNA delivery in cancer immunotherapy
Asthana, G. S., Bhattacharjee, S., Kumar, J., Sayyed, S., Jindal, A., Kumar, P., Chinchane, A., Bhattacharyya, A., Jaiswal, R., Kulkarni, S., et al. (2025) · Advances in immunology · doi:10.1016/bs.ai.2025.02.001 · Cited by 5
Tiwari, A., Gulbake, A. S., & Kumar, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91201-3.00010-4 · Cited by 4
Increasing the success potential of promising biotech companies
Marrus, S. K., & Blaho, J. A. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01627-1 · Cited by 4
Emerging Trends on Nanovaccine Administration and Functionalization Strategies for Immunization
Dewangan, H. K., Shah, K., Sharma, R. K., Sharma, S., Kumar, A., Khan, M. I., Alghamdi, A. A., & Abbas, M. A. E. (2024) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416524500066 · Cited by 5
Curative potential of EGCG based nanoforms in wound infection and wound healing
Sinha, S., Pant, K., Mishra, A., & Anand, J. (2024) · International Journal of Polymeric Materials · doi:10.1080/00914037.2024.2398550 · Cited by 4
“Thus, the conjugate of EGCG-solid lipid nanoparticles could serve as a chemotherapeutic agent [36] .”
Nanomedicines for Brain Diseases: Where we are and where we are Going
Tosi, G., Duskey, J. T., Vandelli, M. A., et al. (2021) · Therapeutic Delivery · doi:10.4155/tde-2021-0051 · Cited by 4
Roffo, F., Orlandella, F. M., Luciano, N., Salvatore, G., & Torino, E. (2026) · Bioengineering · doi:10.3390/bioengineering13020209 · Cited by 3
“The nanomedicine community conducts fundamental and technical research on lipid nanoparticles (LNPs) to investigate and optimize their synthetic and biological identity, allowing for the development of promising therapies at a remarkable speed [1,2].”
Hameed, H., Sarwar, H. S., Younas, K., Zaman, M., Jamshaid, M., Irfan, A., Khalid, M., & Sohail, M. F. (2024) · Functional & Integrative Genomics · doi:10.1007/s10142-024-01459-z · Cited by 3
“The liver produces the majority of the transthyretin protein, which is present in serum and cerebral fluid (Mater 2021).”
Progress and Prospects for Non‐Viral Gene Therapy
Tiwari, S. (2023) · doi:10.1002/9781394175635.ch5 · Cited by 3
Tang, W., Li, Y., Marsh, D. J., Ariotti, N., Cheng, Y. Y., Langford, S. J., & Liao, J. (2024) · Nano Research · doi:10.26599/nr.2025.94907356 · Cited by 2
Nanomaterials Coatings for Aerospace and Defense Applications: Current Prospects and Future Trends
Kumar, S., & Kumar, R. (2025) · Advanced structured materials · doi:10.1007/978-3-031-92723-2_3 · Cited by 2
Gene modification: Exploring the potential in treating kidney diseases
Ekperikpe, U. S., Zhao, S., & Daehn, I. S. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108104 · Cited by 3
Sakhaei, Z., Daryaee, R., Moosavi, A. A., Carrasco-Marín, F., Betancur, S., Bailón‐García, E., Pérez‐Cadenas, A. F., & Riazi, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15397-6.00013-9 · Cited by 3
Metadata
- Venue
- Nature Reviews Materials
- Published
- 2021-02-09
- Volume
- 6
- Issue
- 2
- Pages
- 99-99
- ISSN
- 2058-8437 (ISSN-L)
- OpenAlex
- W4253670085
- Cited by
- 119
- References
- 0
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 26 · 2023: 21 · 2022: 26 · 2021: 22
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature Reviews Materials (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- lipid nanoparticles, mRNA vaccines, COVID-19 pandemic, small molecule delivery, nanomedicine, vaccine delivery vehicles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
